WeiTao Bio Secures Over RMB 100 Million in Angel Funding to Advance In Vivo CAR-T Platform

　　【Pharmaceutical Network Industry DynamicsSince the approval of the first product in 2017, CAR-T therapy has reshaped the landscape of cancer treatment with its breakthrough efficacy in treating hematologic tumors. However, the inherent limitations of the ex vivo manufacturing model have become increasingly prominent. Against this backdrop, in vivo CAR-T technology, which requires no ex vivo manipulation and directly modifies T cells within the patient’s body, has become a core direction for pharmaceutical companies to overcome these bottlenecks.
 

The past two years have become a critical turning point for in vivo CAR-T technology, transitioning from proof of concept to clinical practice. Data shows that currently, there are over 70 in vivo CAR-T pipelines globally in preclinical or early clinical development stages, with the number of pipelines expected to exceed 100 by the end of 2025. The number of clinical trials continues to expand, marking a technological revolution. Many pharmaceutical companies are increasing their investments.
 

IVACTA Biotechnology recently announced the completion of an angel round of financing exceeding 100 million RMB. Data shows that IVACTA Biotechnology is developing an in vivo CAR-T pipeline based on a targeted LNP delivery system, focusing on bringing revolutionary treatments for hematologic tumors and autoimmune diseases. Meanwhile, IVACTA Biotechnology’s targeted LNP delivery system demonstrates outstanding performance in precision, safety, and production compatibility. By utilizing a unique technical approach, it enhances T-cell targeting efficiency, effectively reduces off-target risks, and adapts to scalable manufacturing. The company’s self-developed targeting technology enables efficient activation of T-cells and long-term CAR expression. In multiple preclinical models, it has shown excellent B-cell depletion effects and good safety upon repeated dosing. This round of financing will accelerate the clinical validation of IVACTA Biotechnology and its in vivo CAR-T pipeline.
 

IVACTA Biotechnology is a microcosm of the global CAR-T industry upgrade. Since 2025, multinational pharmaceutical companies have掀起ed a wave of mergers and acquisitions: AstraZeneca acquired EsoBiotec for $1 billion, Kite, a subsidiary of Gilead, acquired Interius for $350 million, and AbbVie made a $2.1 billion bet on Capstan. Leading multinational companies are vying to seize the high ground in CAR-T through capital deployment.
 

The track in China is equally bustling, such as Legend Biotech's development of a bispecific in vivo CAR-T product using the lentivirus approach, with Phase I clinical trials set to commence in May 2025; Jiyin Biotech’s CD19-targeted therapy has achieved complete remission in patients with relapsed or refractory lymphoma without serious side effects. IVACTA Biotechnology, leveraging the differentiated advantages of LNP non-viral delivery technology, has become a significant player in China, forming a "solid tumor + hematologic tumor" synergistic matrix with Gracell Biotechnologies' TIL pipeline, showcasing a platform-based development strategy. As more clinical data becomes available in the future, in vivo technology will drive CAR-T from "high-end customization" towards "universal healthcare."
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.